RxDoctor Payments Data

Connie Pham, MD

Internal Medicine · Houston, TXNPI 1730165648

Payments from drug & device makers

$616in general payments, 2019–2025

Across 13 payments — averaging $47.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$154
  • Teva Pharmaceuticals USA, Inc.$125
  • AbbVie$119
  • Novo Nordisk$79
  • Lilly USA, LLC$73
  • Abbott$22
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$616100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$616 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,940
Medicare patients
22
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol23$35,443
JanuviaSitagliptin Phosphate23$34,964
VascepaIcosapent Ethyl33$29,080
OzempicSemaglutide15$26,660
ProliaDenosumab15$25,772
MyrbetriqMirabegron15$18,439
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,313
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,206
Atorvastatin Calcium342$1,977
Albuterol Sulfate HfaAlbuterol Sulfate48$1,256
Losartan Potassium169$1,141
Metoprolol Succinate90$885
Pantoprazole Sodium77$771
Levocetirizine Dihydrochloride69$727
Levothyroxine Sodium77$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$79$26,66015 claims
AmgenProlia$14$25,77215 claims
Astellas Pharma US IncMyrbetriq$17$18,43915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →